Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 1
1950 1
1951 1
1955 1
1956 1
1957 1
1959 3
1960 2
1961 3
1962 2
1963 5
1964 4
1970 2
1973 1
1974 6
1975 1
1976 4
1977 2
1980 3
1981 1
1982 4
1983 6
1984 6
1985 8
1986 3
1987 7
1988 4
1989 11
1990 9
1991 16
1992 11
1993 7
1994 9
1995 18
1996 13
1997 32
1998 23
1999 28
2000 33
2001 41
2002 35
2003 44
2004 58
2005 68
2006 72
2007 71
2008 112
2009 141
2010 138
2011 152
2012 160
2013 143
2014 180
2015 172
2016 140
2017 161
2018 171
2019 171
2020 195
2021 100
Text availability
Article attribute
Article type
Publication date

Search Results

2,484 results
Results by year
Filters applied: . Clear all
Page 1
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Kato K, et al. Among authors: yen cc. Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30. Lancet Oncol. 2019. PMID: 31582355 Clinical Trial.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Zhu AX, et al. Among authors: yen cj. Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18. Lancet Oncol. 2019. PMID: 30665869 Clinical Trial.
SARS-CoV2 Testing: The Limit of Detection Matters.
Arnaout R, Lee RA, Lee GR, Callahan C, Yen CF, Smith KP, Arora R, Kirby JE. Arnaout R, et al. Among authors: yen cf. bioRxiv. 2020 Jun 4:2020.06.02.131144. doi: 10.1101/2020.06.02.131144. Preprint. bioRxiv. 2020. PMID: 32577640 Free PMC article.
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.
Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK. Kim RD, et al. Among authors: yen cj. Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1. Cancer Discov. 2019. PMID: 31575541 Free article. Clinical Trial.
Pan-viral serology implicates enteroviruses in acute flaccid myelitis.
Schubert RD, Hawes IA, Ramachandran PS, Ramesh A, Crawford ED, Pak JE, Wu W, Cheung CK, O'Donovan BD, Tato CM, Lyden A, Tan M, Sit R, Sowa GA, Sample HA, Zorn KC, Banerji D, Khan LM, Bove R, Hauser SL, Gelfand AA, Johnson-Kerner BL, Nash K, Krishnamoorthy KS, Chitnis T, Ding JZ, McMillan HJ, Chiu CY, Briggs B, Glaser CA, Yen C, Chu V, Wadford DA, Dominguez SR, Ng TFF, Marine RL, Lopez AS, Nix WA, Soldatos A, Gorman MP, Benson L, Messacar K, Konopka-Anstadt JL, Oberste MS, DeRisi JL, Wilson MR. Schubert RD, et al. Among authors: yen c. Nat Med. 2019 Nov;25(11):1748-1752. doi: 10.1038/s41591-019-0613-1. Epub 2019 Oct 21. Nat Med. 2019. PMID: 31636453 Free PMC article.
CPAP promotes angiogenesis and metastasis by enhancing STAT3 activity.
Chen RY, Yen CJ, Liu YW, Guo CG, Weng CY, Lai CH, Wang JM, Lin YJ, Hung LY. Chen RY, et al. Among authors: yen cj. Cell Death Differ. 2020 Apr;27(4):1259-1273. doi: 10.1038/s41418-019-0413-7. Epub 2019 Sep 11. Cell Death Differ. 2020. PMID: 31511651 Free PMC article.
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, Le Cesne A, Van Tine BA, Naito Y, Park SH, Fedenko A, Pápai Z, Soldatenkova V, Shahir A, Mo G, Wright J, Jones RL; ANNOUNCE Investigators. Tap WD, et al. Among authors: yen cc. JAMA. 2020 Apr 7;323(13):1266-1276. doi: 10.1001/jama.2020.1707. JAMA. 2020. PMID: 32259228 Free PMC article. Clinical Trial.
2,484 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page